Conventus Flower Orthopedics receives FDA clearance for ulnar intramedullary nail system

Fact checked byGina Brockenbrough, MA

Conventus Flower Orthopedics has announced FDA 510(k) clearance of its Flex-Thread Ulna Intramedullary Nail System for use in the fixation of fractures and osteotomies of the ulna, according to a press release.

The Flex-Thread Ulna Intramedullary Nail System is expected to launch in February 2023, according to the release.

FDA HQ in Washington — Conventus Flower Orthopedics received FDA 510(k) clearance of its Flex-Thread Ulna Intramedullary Nail System. Source: Adobe Stock

“We are excited to introduce our second system within our Flex-Thread platform. The Flex-Thread Ulna Intramedullary Nail System demonstrates our continued commitment to introducing innovative and differentiated technology to the market,” Brad Niemann, CEO of Conventus Flower Orthopedics, said in the release. “With over 650 cases utilizing our Flex-Thread Distal Fibula Nail System, we have seen tremendous results and have been extremely pleased with the adoption of this unique technology. We expect the Flex-Thread Ulna Intramedullary Nail System to be well received and a terrific option for fracture management in the upper extremity market segment,” Niemann said.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Conventus Flower Orthopedics receives FDA clearance for ulnar intramedullary nail system

Related Content